Gapping down
In reaction to disappointing earnings/guidance: BODY -22.8%, REED -12.5%, RGSE -9.8%, GEVO -9.7%, IGT -7.4%, LNDC -1.8% (light volume), PNRA -1.7% (also downgraded to Hold at Wunderlich on lower margins).
Select battery related names pulling back: PLUG -5.7%, CPST -3.8%, BLDP -3.7%, FCEL -3.4%.
A few financial names are trading lower: RBS -2%, LYG -1.6% (continued weakness)
Other news: GGS -63.8% (files voluntary Chapter 11 petitions to facilitate financial restructuring), INSM -30.1% (announces results from Phase 2 clinical trial for treatment resistant nontuberculous mycobacterial lung infections; ARIKAYCE did not meet the pre-specified level for statistical significance, however, ARIKAYCE did achieve statistical significance with regard to the clinically relevant key secondary endpoint of culture conversion), EXEL -22.4% (provides update on ongoing COMET-1 Phase 3 Pivotal trial in men with metastatic castration-resistant prostate cancer), GCA -18% ( announces that its cash access agreements with Caesars Entertainment will not be renewed; reaffirms adjusted EBITDA and cash EPS estimates for FY14 ), BFAM -5.4% (announces secondary offering of 7 mln shares of common stock by selling stockholders), SZYM -2.6% (announces proposed offering of $100 mln of convertible senior subordinated notes due 2019 and 5 mln shares of common stock in separate offerings), VEEV -2.1% (prices offering of 12 mln shares of common stock at a price to the public of $26.35 per share by co and selling shareholders), CCL-1.4% (following yesterday's earnings), ESS -1.1% (announces sale of 450,000 shares of common stock under equity distribution agreement), ECYT -1.1% (files mixed securities shelf offering; announces proposed offering of 4.5 mln shares of its common stock; announces proposed offering of 4.5 mln shares of its common stock), ZNGA -0.8% (following FB news), BYI -0.7% (following IGT guidance), BID -0.6% ( issues response to Third Point litigation: 'Continues to believe that the Board's decisions to adopt and maintain the 12-month rights plan are both valid and legal' ), GSK -0.2% (withdraws its MAA to the European Medicines Agency for the use of Mekinist (trametinib) in combination with previously approved BRAF inhibitor Tafinlar (dabrafenib) for treatment of adult patients with unresectable or metastatic melanoma with a BRAF V600 mutation).
Analyst comments: TEF -1.4% (ticking lower; downgraded to Underperform from Neutral at BofA/Merrill), ACI -0.6% and CNX -0.4% (downgraded to Neutral from Buy at UBS), HME -0.3% (downgraded to Neutral from Buy at Citigroup)
Select battery related names pulling back: PLUG -5.7%, CPST -3.8%, BLDP -3.7%, FCEL -3.4%.
A few financial names are trading lower: RBS -2%, LYG -1.6% (continued weakness)
Other news: GGS -63.8% (files voluntary Chapter 11 petitions to facilitate financial restructuring), INSM -30.1% (announces results from Phase 2 clinical trial for treatment resistant nontuberculous mycobacterial lung infections; ARIKAYCE did not meet the pre-specified level for statistical significance, however, ARIKAYCE did achieve statistical significance with regard to the clinically relevant key secondary endpoint of culture conversion), EXEL -22.4% (provides update on ongoing COMET-1 Phase 3 Pivotal trial in men with metastatic castration-resistant prostate cancer), GCA -18% ( announces that its cash access agreements with Caesars Entertainment will not be renewed; reaffirms adjusted EBITDA and cash EPS estimates for FY14 ), BFAM -5.4% (announces secondary offering of 7 mln shares of common stock by selling stockholders), SZYM -2.6% (announces proposed offering of $100 mln of convertible senior subordinated notes due 2019 and 5 mln shares of common stock in separate offerings), VEEV -2.1% (prices offering of 12 mln shares of common stock at a price to the public of $26.35 per share by co and selling shareholders), CCL-1.4% (following yesterday's earnings), ESS -1.1% (announces sale of 450,000 shares of common stock under equity distribution agreement), ECYT -1.1% (files mixed securities shelf offering; announces proposed offering of 4.5 mln shares of its common stock; announces proposed offering of 4.5 mln shares of its common stock), ZNGA -0.8% (following FB news), BYI -0.7% (following IGT guidance), BID -0.6% ( issues response to Third Point litigation: 'Continues to believe that the Board's decisions to adopt and maintain the 12-month rights plan are both valid and legal' ), GSK -0.2% (withdraws its MAA to the European Medicines Agency for the use of Mekinist (trametinib) in combination with previously approved BRAF inhibitor Tafinlar (dabrafenib) for treatment of adult patients with unresectable or metastatic melanoma with a BRAF V600 mutation).
Analyst comments: TEF -1.4% (ticking lower; downgraded to Underperform from Neutral at BofA/Merrill), ACI -0.6% and CNX -0.4% (downgraded to Neutral from Buy at UBS), HME -0.3% (downgraded to Neutral from Buy at Citigroup)